Group members

Garcia-Foncillas J, Bayle A, Arnold D, Avouac B, Awada A, de la Cruz-Merino L, Helland Å, Lassen U, Laurent-Puig P, Normanno N, Rohrberg K, Taieb J, Stenzinger A (2025)
Overcoming barriers to advanced biomolecular technologies that inform treatment of solid tumors: a roadmap to access
Future Oncol, 21 (14), 1745-1752
DOI 10.1080/14796694.2025.2501523, PubMed 40340714

Grønberg BH, Killingberg KT, Fløtten Ø, Bjaanæs MM, Brustugun OT, Madebo T, Langer SW, Risumlund SL, Schytte T, Helbekkmo N, Neumann K, Yksnøy Ø, Engleson J, Fluge S, Naustdal T, Giske LE, Nyman J, Tsakonas G, Halvorsen TO (2025)
High-Dose Versus Standard-Dose Twice-Daily Thoracic Radiotherapy in Limited-Stage SCLC: Final Survival Data, Long-Term Toxicity, and Relapse Patterns in a Randomized, Open-Label, Phase II Trial
J Thorac Oncol (in press)
DOI 10.1016/j.jtho.2025.04.007, PubMed 40258573

Hermansen JU, Athanasiadis P, Yin Y, Rise AF, Arribas AJ, Cascione L, Russnes HG, Helland Å, Mato AR, Bertoni F, Tjønnfjord GE, Aittokallio T, Skånland SS (2025)
Proteasome inhibition overcomes resistance to targeted therapies in B-cell malignancy models and in an index patient
Cell Death Dis, 16 (1), 555
DOI 10.1038/s41419-025-07884-7, PubMed 40701968